Skip to content

Study · Randomized controlled trial · 2023

7 results

Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial.

Naimi RM, Hvistendahl MK, Poulsen SS, Kissow H, Pedersen J, Nerup NA, Ambrus R, Achiam MP, Svendsen LB, Jeppesen PB

JPEN. Journal of parenteral and enteral nutrition31 May 2022Cited by 21 (Europe PMC)

PMID35511704 (opens in a new tab)PMCIDPMC10084040 (opens in a new tab)DOI10.1002/jpen.2389 (opens in a new tab)PepBankPUB-35511704
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide increased plasma citrulline by 15.3 µmol/L from baseline (P = 0.001).

    In plain wordsIn patients with short bowel syndrome, glepaglutide increased plasma citrulline from baseline.

    Peptide
    Glepaglutide
    Outcome
    IncreasePlasma citrulline
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    1 mg · three weeksAs given in this study (human).

    Measurements

    Change in plasma citrulline
    15.3 µmol/L
    1-mg dose group, change from baseline

    Source sentences

    Summary
    In the 1- and 10-mg dose groups, glepaglutide significantly increased plasma citrulline by 15.3 µmol/L (P = 0.001) and 15.6 µmol/L (P = 0.001), respectively.
    1 context sentence
    Summary · context
    The following assessments were done in 18 patients with SBS in a randomized, crossover, dose-finding, phase 2 trial before and after three weeks of treatment with glepaglutide:
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide increased plasma citrulline by 15.6 µmol/L from baseline (P = 0.001).

    In plain wordsIn patients with short bowel syndrome, glepaglutide increased plasma citrulline from baseline.

    Peptide
    Glepaglutide
    Outcome
    IncreasePlasma citrulline
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    10 mg · three weeksAs given in this study (human).

    Measurements

    Change in plasma citrulline
    15.6 µmol/L
    10-mg dose group, change from baseline

    Source sentences

    Summary
    In the 1- and 10-mg dose groups, glepaglutide significantly increased plasma citrulline by 15.3 µmol/L (P = 0.001) and 15.6 µmol/L (P = 0.001), respectively.
    1 context sentence
    Summary · context
    The following assessments were done in 18 patients with SBS in a randomized, crossover, dose-finding, phase 2 trial before and after three weeks of treatment with glepaglutide:
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide showed a trend toward increased villus height from baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide showed a trend toward increased villus height from baseline.

    Peptide
    Glepaglutide
    Outcome
    IncreaseVillus height
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    1 and 10 mg · three weeksAs given in this study (human).

    Source sentences

    Summary
    Trends toward an increase in villus height, crypt depth, and epithelium height were seen in the same groups.
    2 context sentences
    Summary · context
    In the 1- and 10-mg dose groups, glepaglutide significantly increased plasma citrulline by 15.3 µmol/L (P = 0.001) and 15.6 µmol/L (P = 0.001), respectively.
    Summary · context
    The following assessments were done in 18 patients with SBS in a randomized, crossover, dose-finding, phase 2 trial before and after three weeks of treatment with glepaglutide:
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide showed a trend toward increased crypt depth from baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide showed a trend toward increased crypt depth from baseline.

    Peptide
    Glepaglutide
    Outcome
    IncreaseCrypt depth
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    1 and 10 mg · three weeksAs given in this study (human).

    Source sentences

    Summary
    Trends toward an increase in villus height, crypt depth, and epithelium height were seen in the same groups.
    2 context sentences
    Summary · context
    In the 1- and 10-mg dose groups, glepaglutide significantly increased plasma citrulline by 15.3 µmol/L (P = 0.001) and 15.6 µmol/L (P = 0.001), respectively.
    Summary · context
    The following assessments were done in 18 patients with SBS in a randomized, crossover, dose-finding, phase 2 trial before and after three weeks of treatment with glepaglutide:
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide showed a trend toward increased epithelium height from baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide showed a trend toward increased epithelium height from baseline.

    Peptide
    Glepaglutide
    Outcome
    IncreaseEpithelium height
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Intestinal growth and absorption · Gastrointestinal
    Studied dose
    1 and 10 mg · three weeksAs given in this study (human).

    Source sentences

    Summary
    Trends toward an increase in villus height, crypt depth, and epithelium height were seen in the same groups.
    2 context sentences
    Summary · context
    In the 1- and 10-mg dose groups, glepaglutide significantly increased plasma citrulline by 15.3 µmol/L (P = 0.001) and 15.6 µmol/L (P = 0.001), respectively.
    Summary · context
    The following assessments were done in 18 patients with SBS in a randomized, crossover, dose-finding, phase 2 trial before and after three weeks of treatment with glepaglutide:
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide did not significantly change intestinal gene expressions from baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide did not significantly change intestinal gene expressions from baseline.

    Peptide
    Glepaglutide
    Outcome
    No significant changeIntestinal gene expressions
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated · three weeksAs given in this study (human).

    Source sentences

    Summary
    No significant changes were seen in gene expressions or intestinal perfusion.
    1 context sentence
    Summary · context
    The following assessments were done in 18 patients with SBS in a randomized, crossover, dose-finding, phase 2 trial before and after three weeks of treatment with glepaglutide:
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide did not significantly change intestinal perfusion from baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide did not significantly change intestinal perfusion from baseline.

    Peptide
    Glepaglutide
    Outcome
    No significant changeIntestinal perfusion
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Vascular function · Gastrointestinal
    Studied dose
    Dose not stated · three weeksAs given in this study (human).

    Source sentences

    Summary
    No significant changes were seen in gene expressions or intestinal perfusion.
    1 context sentence
    Summary · context
    The following assessments were done in 18 patients with SBS in a randomized, crossover, dose-finding, phase 2 trial before and after three weeks of treatment with glepaglutide:

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.